Literature DB >> 8319173

Long-term results of postoperative intrathoracic chemo-thermotherapy for lung cancer with pleural dissemination.

K Kodama1, O Doi, M Higashiyama, H Yokouchi, M Tatsuta.   

Abstract

BACKGROUND: To overcome the poor prognosis of lung cancer with pleural dissemination, the authors developed postoperative intrathoracic chemo-thermotherapy (PICT). In this report, they present the long-term results for 31 consecutive patients who underwent resection, followed by PICT for lung cancer with pleural dissemination between April 1985 and December 1991.
METHODS: Among the patients, there were 26 cases of adenocarcinoma, 3 cases of squamous cell carcinoma, and 1 case each of large and adenosquamous cell carcinoma. Twenty-four of these patients had an initial diagnosis of pleural involvement at thoracotomy. The other seven patients had massive malignant effusion at the time of the initial diagnosis. PICT was started between days 10 to 14 postoperatively. When possible, three courses of this procedure were administered at intervals of 5-7 days.
RESULTS: The 5-year cumulative and 5-year local relapse-free survival rates were 24.6% and 76.3%, respectively. The 3-year and 5-year cumulative survival rates for 14 patients without mediastinal lymph node involvement were 68.4% and 42.7%, respectively. Those rates for 17 patients with mediastinal lymph node involvement were 22.7% and 0%, respectively. The 3-year survival rate in the former group was significantly better than that in the latter group.
CONCLUSIONS: These results strongly suggest that in patients with pleural dissemination, PICT may be beneficial for regional disease control and improvement of survival, particularly for patients without mediastinal lymph node involvement.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8319173     DOI: 10.1002/1097-0142(19930715)72:2<426::aid-cncr2820720218>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  In lung cancer patients where a malignant pleural effusion is found at operation could resection ever still be justified?

Authors:  Alfonso Fiorelli; Mario Santini
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-05-08

2.  Role of surgery in multi-modality treatment for carcinomatous pleuritis in patients with non-small cell lung cancer.

Authors:  Tetsuhiko Go; Noriyuki Misaki; Natsumi Matsuura; Sung Soo Chang; Shintarou Tarumi; Hiroyasu Yokomise
Journal:  Surg Today       Date:  2014-07-19       Impact factor: 2.549

Review 3.  Heating technology for malignant tumors: a review.

Authors:  H Petra Kok; Erik N K Cressman; Wim Ceelen; Christopher L Brace; Robert Ivkov; Holger Grüll; Gail Ter Haar; Peter Wust; Johannes Crezee
Journal:  Int J Hyperthermia       Date:  2020       Impact factor: 3.914

4.  Intrapleural hyperthermic perfusion using distilled water at 48 °C for malignant pleural effusion.

Authors:  Mingchen Ba; Hui Long; Yuandong Wang; Yunqiang Tang; Yinbing Wu; Xiangliang Zhang; Shuzhong Cui
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-26       Impact factor: 4.553

5.  Clinical value of pleural lavage cytological positivity in lung cancer patients without intraoperative malignant pleuritis. Recurrent pattern based on semiquantitative analysis of tumor cells in pleural lavage.

Authors:  M Higashiyama; K Kodama; H Yokouchi; K Takami; T Nakayama; T Horai
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-10

6.  The efficacy and safety of intrapleural hyperthermic perfusion in patients with malignant pleural effusion undergoing video-assisted thoracic surgery: a single-arm clinical trial.

Authors:  Xinxin Wang; Min Kong; Jiang Jin; Yulian Lin; Limin Jia; Minhua Ye
Journal:  J Thorac Dis       Date:  2022-05       Impact factor: 3.005

Review 7.  Current status of oncothermia therapy for lung cancer.

Authors:  Andras Szasz
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2014-04-10

8.  Long-Term Treatment-Free Survival After Multimodal Therapy in a Patient with Stage IV Lung Adenocarcinoma.

Authors:  Hatsuyo Takaoka; Hideki Terai; Katsura Emoto; Lisa Shigematsu; Fumimaro Ito; Ayaka Saito; Masahiko Okada; Keiko Ohgino; Shinnosuke Ikemura; Hiroyuki Yasuda; Ichiro Nakachi; Ichiro Kawada; Koichi Fukunaga; Kenzo Soejima
Journal:  Onco Targets Ther       Date:  2022-09-14       Impact factor: 4.345

9.  The prognostic analysis of lung cancer patients with occult malignant pleural disease at thoracotomy.

Authors:  Shaolei Li; Xin Yang; Shanyuan Zhang; Miao Huang; Yuanyuan Ma; Yue Yang
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.